Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine

被引:55
作者
Wise, RP
Iskander, J
Pratt, RD
Campbell, S
Ball, R
Pless, RP
Braun, MM
机构
[1] US FDA, Ctr Biol Evaluat & Res, Div Epidemiol, Off Biostat & Epidemiol, Rockville, MD 20852 USA
[2] US FDA, Ctr Biol Evaluat & Res, Div Vaccines & Related Prod Applicat, Off Vaccines Res & Review, Rockville, MD 20852 USA
[3] Ctr Dis Control & Prevent, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA USA
[4] Ctr Infect Dis Prevent & Control Hlth Canada, Immunizat Safety Unit, Immunizat & Resp Infect Div, Ottawa, ON, Canada
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2004年 / 292卷 / 14期
关键词
D O I
10.1001/jama.292.14.1702
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Clinical trials evaluate a vaccine's safety before approval, but some risks may escape detection or adequate characterization until larger population exposures occur after licensure. Objective To summarize reports of events occurring after vaccination with 7-valent pneumococcal conjugate vaccine (PCV), including those that may warrant further investigation to assess possible causation by PCV. Design Descriptive epidemiology of reports submitted to the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance database. Setting and Patients United States during first 2 years after licensure of PCV (February 2000 through February 2002). Reports studied were for children younger than 18 years and vaccinated with PCV. Main Outcome Measures Numbers and proportional distributions of reports. Results A total of 4154 reports of events following PCV were submitted to VAERS, for a rate of 13.2 reports per 100000 doses distributed. Multiple vaccines were given in 74.3% of reports. The most frequently reported symptoms and signs included fever, injection site reactions, fussiness, rashes, and urticaria. Serious events were described in 14.6% of reports. There were 117 deaths, 23 reports of positive rechallenges, and 34 cases of invasive pneumococcal infections possibly representing vaccine failure. Immune-mediated events occurred in 31.3% of reports. All 14 patients with anaphylactic or anaphylactoid reactions survived. Thrombocytopenia developed in 14 patients and serum sickness in 6 others. Neurologic symptoms occurred in 38% of reports. Seizures described in 393 reports included 94 febrile seizures. Conclusions The majority of reports to VAERS in the first 2 years after licensure of PCV described generally minor adverse events previously identified in clinical trials. The proportion of reports portraying serious events was similar to that for other vaccines. Although there are important limitations in passive surveillance data, and caution in their interpretation is necessary, symptoms experienced by a few children more than once after successive PCV doses, including allergic reactions, prolonged or abnormal crying, fussiness, dyspnea, and gastrointestinal distress, warrant continued surveillance, as do reports of rare but potentially serious events, such as seizures, anaphylactic or anaphylactoid reactions, serum sickness, and thrombocytopenia.
引用
收藏
页码:1702 / 1710
页数:9
相关论文
共 33 条
  • [1] Ball Robert, 2002, Expert Rev Vaccines, V1, P161, DOI 10.1586/14760584.1.2.161
  • [2] Thrombocytopenia after immunization with measles vaccines: Review of the vaccine adverse events reporting system (1990 to 1994)
    Beeler, J
    Varricchio, F
    Wise, R
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (01) : 88 - 90
  • [3] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
    Black, S
    Shinefield, H
    Fireman, B
    Lewis, E
    Ray, P
    Hansen, JR
    Elvin, L
    Ensor, KM
    Hackell, J
    Siber, G
    Malinoski, F
    Madore, D
    Chang, I
    Kohberger, R
    Watson, W
    Austrian, R
    Edwards, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 187 - 195
  • [4] Lack of association between receipt of conjugate Haemophilus influenzae type b vaccine (HbOC) in infancy and risk of type 1 (juvenile onset) diabetes:: Long term follow-up of the HbOC efficacy trial cohort
    Black, SB
    Lewis, E
    Shinefield, HR
    Fireman, B
    Ray, P
    DeStefano, F
    Chen, R
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (06) : 568 - 569
  • [5] Descriptive epidemiology of adverse events after immunization: Reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994
    Braun, MM
    Ellenberg, SS
    [J]. JOURNAL OF PEDIATRICS, 1997, 131 (04) : 529 - 535
  • [6] Byard RW, 1998, J PAEDIATR CHILD H, V34, P101
  • [7] Vaccination and SIDS: Information from the South Australian SIDS Database
    Byard, RW
    Mackenzie, J
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1995, 163 (08) : 443 - 444
  • [8] THE VACCINE-ADVERSE-EVENT-REPORTING-SYSTEM (VAERS)
    CHEN, RT
    RASTOGI, SC
    MULLEN, JR
    HAYES, SW
    COCHI, SL
    DONLON, JA
    WASSILAK, SG
    [J]. VACCINE, 1994, 12 (06) : 542 - 550
  • [9] Vaccine-induced autoimmunity
    Cohen, AD
    Shoenfeld, Y
    [J]. JOURNAL OF AUTOIMMUNITY, 1996, 9 (06) : 699 - 703
  • [10] Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus
    DeStefano, F
    Mullooly, JP
    Okoro, CA
    Chen, RT
    Marcy, SM
    Ward, JI
    Vadheim, CM
    Black, SB
    Shinefield, HR
    Davis, RL
    Bohlke, K
    [J]. PEDIATRICS, 2001, 108 (06) : E112